SCEMBLIX®▼ (askiminib)

SCEMBLIX er indisert til behandling av voksne med Philadelphiakromosom-positiv kronisk myelogen leukemi i kronisk fase (Ph+ KML-KF).¹

Referanser:
1. SCEMBLIX (askiminib) SPC, avsnitt 2
2. Chen EY, Dahlen T, Stenke L, Bjorkholm M, Hao S, Dickman PW, et al. Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia. Eur J Haematol. 2025;114(2):334-42.
3. Garcia-Horton A, Lipton JH. Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All? J Natl Compr Canc Netw. 2020;18(10):1421-8.
4. Mikhaeel S, Atallah E. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML). Clin Lymphoma Myeloma Leuk. 2023;23(5):333-9.
5. Rea D, Hughes TP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol. 2022;171:103580.
6. Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, et al. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026;147(13):1433-46.
7. Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up 
of ASCEMBL. Leukemia. 2023;37(3):617-26.
8. Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024;391(10):885-98.
9. Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031-41.